Завод ДИОД logo
Завод ДИОД DIOD

Завод ДИОД Financial Ratios 2007-2025 | DIOD

Annual Financial Ratios Завод ДИОД

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Price Earnings Ratio, P/E

171.2 17.39 8.02 18.37 6.76 34.25 -17.77 -2.12 -3.2 5.41 -2.3 46.55 11.82 18.46 7.83 0.0 0.0

Price Sales Ratio, P/S

2.63 1.25 1.21 1.32 0.66 0.49 0.56 0.34 0.4 0.24 0.32 0.55 0.97 1.94 1.88 0.0 0.0

Price To Book Ratio, P/B

1.27 0.58 0.59 0.57 0.36 0.32 0.34 0.21 0.25 0.18 0.22 0.35 0.82 1.65 1.71 0.0 0.0

Price Earnings To Growth Ratio, PEG

-2.16 -0.31 0.05 -0.4 0.01 -0.24 0.22 -0.12 0.01 -0.04 0.0 -0.52 -0.55 -0.33 -0.08 -0.0 -

Operating Cash Flow Per Share

0.03 0.0 0.0 0.0 1.85 0.0 0.0 -0.0 - - - - - - - - 15370.93

Free Cash Flow Per Share

-0.35 0.0 -0.12 -0.01 1.83 -0.17 0.0 -0.0 1.13 0.57 -0.36 -0.02 -0.07 -0.19 -0.24 -3745.79 15117.49

Cash Per Share

0.37 2.29 1.93 1.31 0.33 1.12 0.92 0.99 1.57 0.02 0.15 0.19 0.19 0.42 0.42 3126.89 2527.87

Payout Ratio

8.63 0.0 0.6 1.04 0.6 3.03 -0.0 -0.0 -0.09 0.42 -0.07 1.67 0.42 0.06 0.07 0.04 -

Dividend Yield

0.05 0.0 0.07 0.06 0.09 0.09 0.0 0.0 0.03 0.08 0.03 0.04 0.04 0.0 0.01 45.31 -

Current Ratio

6.72 7.56 9.22 8.75 5.75 5.02 4.95 5.72 3.11 1.82 2.44 3.76 2.94 2.9 1.73 2.44 2.26

Quick Ratio

4.22 4.65 5.61 4.92 3.14 2.67 2.12 2.26 1.26 0.8 1.45 2.4 1.97 1.74 0.84 1.18 1.42

Cash Ratio

0.26 0.87 0.87 0.47 0.03 0.17 0.04 0.06 0.38 0.0 0.02 0.04 0.03 0.08 0.05 0.06 0.06

Days Of Sales Outstanding, DSO

204.37 - 213.41 251.13 239.58 172.78 114.3 110.19 106.68 104.26 213.96 251.45 182.99 192.83 131.91 108.46 123.35

Days Of Inventory Outstanding, DIO

466.79 540.78 545.11 767.96 505.37 477.25 467.31 459.56 800.12 470.68 611.43 517.97 279.75 276.4 321.55 313.16 180.94

Days Of Payables Outstanding, DPO

21.45 21.07 46.49 144.57 141.34 93.18 99.01 39.08 121.37 70.69 55.61 0.34 49.18 17.54 22.52 26.11 11.36

Operating Cycle

671.16 540.78 758.51 1019.1 744.95 650.03 581.61 569.75 906.8 574.94 825.38 769.42 462.73 469.22 453.47 421.62 304.3

Cash Conversion Cycle

649.71 519.71 712.02 874.53 603.61 556.85 482.6 530.67 785.43 504.26 769.77 769.08 413.55 451.68 430.95 395.51 292.93

Gross Profit Margin

0.54 0.57 0.59 0.63 0.54 0.58 0.5 0.45 0.67 0.55 0.65 0.6 0.54 0.51 0.53 0.61 0.58

Operating Profit Margin

0.0 0.08 0.18 0.14 0.15 0.07 -0.06 0.06 0.1 0.14 0.16 0.14 0.19 0.2 0.34 0.26 0.21

Pretax Profit Margin

0.02 0.11 0.19 0.11 0.12 0.06 -0.03 -0.15 -0.11 0.06 -0.12 0.02 0.1 0.11 0.26 0.24 0.21

Net Profit Margin

0.02 0.07 0.15 0.07 0.1 0.01 -0.03 -0.16 -0.12 0.04 -0.14 0.01 0.08 0.11 0.24 0.17 0.14

Effective Tax Rate

0.37 0.29 0.23 0.39 0.19 0.78 0.39 -0.05 -0.13 0.28 -0.15 0.68 0.25 0.21 0.11 0.26 0.3

Return On Assets, ROA

0.01 0.03 0.06 0.03 0.04 0.01 -0.02 -0.08 -0.06 0.02 -0.06 0.0 0.04 0.05 0.12 0.13 0.15

Return On Equity, ROE

0.01 0.03 0.07 0.03 0.05 0.01 -0.02 -0.1 -0.08 0.03 -0.1 0.01 0.07 0.09 0.22 0.22 0.21

Return On Capital Employed, ROCE

0.0 0.03 0.08 0.06 0.08 0.05 -0.03 0.03 0.06 0.1 0.09 0.06 0.1 0.11 0.22 0.24 0.28

Net Income Per Ebt

0.63 0.67 0.79 0.65 0.8 0.23 0.98 1.05 1.13 0.71 1.15 0.54 0.85 0.99 0.91 0.74 0.68

Ebt Per Ebit

7.37 1.33 1.07 0.78 0.81 0.83 0.58 -2.71 -1.15 0.44 -0.75 0.15 0.52 0.55 0.78 0.89 1.01

Ebit Per Revenue

0.0 0.08 0.18 0.14 0.15 0.07 -0.06 0.06 0.1 0.14 0.16 0.14 0.19 0.2 0.34 0.26 0.21

Debt Ratio

- - 0.03 0.0 0.01 0.05 0.03 0.01 0.01 0.18 0.3 0.3 0.21 0.18 0.17 0.22 0.12

Debt Equity Ratio

- - 0.04 0.0 0.01 0.06 0.04 0.01 0.01 0.27 0.51 0.52 0.4 0.34 0.31 0.38 0.17

Long Term Debt To Capitalization

- - - - 0.03 0.01 0.01 0.01 0.0 0.0 0.17 0.28 0.2 0.17 0.04 0.18 -

Total Debt To Capitalization

- - 0.04 0.0 0.01 0.06 0.04 0.01 0.01 0.21 0.34 0.34 0.29 0.25 0.24 0.27 0.14

Interest Coverage

- 1222.43 5633.42 127.13 28.15 - -1.98 1.33 0.82 1.95 1.83 1.67 3.25 3.23 4.52 10.37 164.81

Cash Flow To Debt Ratio

- - 0.0 0.07 21.21 0.0 0.0 -0.0 - - - - - - - - 0.77

Company Equity Multiplier

1.19 1.17 1.15 1.16 1.2 1.21 1.21 1.19 1.31 1.5 1.7 1.72 1.96 1.84 1.81 1.72 1.45

Receivables Turnover

1.79 - 1.71 1.45 1.52 2.11 3.19 3.31 3.42 3.5 1.71 1.45 1.99 1.89 2.77 3.37 2.96

Payables Turnover

17.01 17.32 7.85 2.52 2.58 3.92 3.69 9.34 3.01 5.16 6.56 1063.66 7.42 20.81 16.21 13.98 32.12

Inventory Turn Over

0.78 0.67 0.67 0.48 0.72 0.76 0.78 0.79 0.46 0.78 0.6 0.7 1.3 1.32 1.14 1.17 2.02

Fixed Asset Turnover

2.2 2.16 2.23 1.93 2.39 3.12 3.12 3.28 3.42 4.38 3.74 3.62 3.17 3.42 3.52 4.31 4.23

Asset Turnover

0.41 0.4 0.42 0.37 0.45 0.54 0.51 0.53 0.47 0.51 0.41 0.37 0.43 0.46 0.5 0.74 1.03

Operating Cash Flow Sales Ratio

0.01 0.0 0.0 0.0 0.26 0.0 0.0 -0.0 - - - - - - - - 0.09

Free Cash Flow Operating Cash Flow Ratio

-10.39 0.97 -103.26 -10.64 0.99 -295.91 0.62 1.02 - - - - - - - - 0.98

Cash Flow Coverage Ratios

- - 0.0 0.07 21.21 0.0 0.0 -0.0 - - - - - - - - 0.77

Short Term Coverage Ratios

- - 0.02 0.07 21.21 0.0 0.0 -0.01 - - - - - - - - 0.77

Capital Expenditure Coverage Ratio

0.09 36.09 0.01 0.09 83.3 0.0 2.61 -41.64 - - - - - - - - 60.65

Dividend Paid And Capex Coverage Ratio

0.03 1.38 0.0 0.0 4.18 0.0 1.19 -41.22 - - - - - - - - 60.65

Dividend Payout Ratio

8.63 0.0 0.6 1.04 0.6 3.03 -0.0 -0.0 -0.09 0.42 -0.07 1.67 0.42 0.06 0.07 0.04 -

Price To Free Cash Flows Ratio, P/FCF

-45.1 7196.53 -67.86 -719.95 2.58 -24.09 9568.71 -3567.51 3.71 5.91 -10.84 -387.96 -232.77 -171.45 -132.63 -0.01 0.0

Price To Operating Cash Flows Ratio, P/OCF

468.51 6997.11 7007.48 7657.5 2.55 7128.65 5897.15 -3653.19 - - - - - - - - 0.0

Price Cash Flow Ratio, P/CF

468.51 6997.11 7007.48 7657.5 2.55 7128.65 5897.15 -3653.19 - - - - - - - - 0.0

Enterprise Value Multiple, EV

62.85 9.12 5.22 8.22 4.02 4.62 14.36 -4.61 20.81 4.11 186.13 10.26 8.9 13.84 6.0 1.08 0.44

Price Fair Value, P/FV

1.27 0.58 0.59 0.57 0.36 0.32 0.34 0.21 0.25 0.18 0.22 0.35 0.82 1.65 1.71 0.0 0.0

All numbers in RUB currency

Quarterly Financial Ratios Завод ДИОД

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q4 2008-Q2

Price Earnings Ratio, P/E

69.1 6.56 K 12 6.38 3.72 5.6 15.9 14.3 1.99 -10.2 5.66 -1.93 2.64 -2.18 -0.813 -1.21 -2.36 2.7 3.38 8.69 -1.13 5.91 8.06 9.23 8.68 3.92 3.92 0.001 0.0

Price Sales Ratio, P/S

4.24 2.7 K 2.47 2.48 3 2.19 2.35 1.35 1.35 0.987 1.18 1.26 0.795 0.723 0.733 0.7 0.93 0.482 0.603 0.565 1.51 1.95 2.66 3.88 3.64 3.76 3.76 0.0 0.0

Price To Book Ratio, P/B

1.01 0.582 0.632 0.588 0.767 0.541 0.419 0.357 0.379 0.322 0.346 0.345 0.256 0.211 0.239 0.247 0.236 0.184 0.236 0.222 0.229 0.816 1.12 1.65 1.6 1.71 1.9 - 0.0

Price Earnings To Growth Ratio, PEG

0.003 -65.7 -0.265 -0.117 0.033 0.022 1.75 -0.165 -0.003 0.07 -0.043 0.007 -0.013 0.032 -0.023 -0.013 0.01 - 0.019 -0.077 0.001 - -0.377 - -0.154 - -0.039 - -0.0

Operating Cash Flow Per Share

0.017 0.0 0.72 0.405 0.762 0.627 0.342 0.491 1.39 0.56 - 0.001 -0.0 -0.0 -0.0 - - - - - - - - - - - - - -

Free Cash Flow Per Share

-0.175 0.0 0.711 0.344 0.704 0.616 0.342 0.541 1.31 0.528 -0.087 0.001 -0.0 -0.0 -0.0 0.566 0.566 0.286 0.286 -0.182 -0.182 -0.035 -0.035 -0.096 -0.096 -0.121 -0.121 -936 -1.87 K

Cash Per Share

2.52 2.3 2.66 1.93 2.12 1.37 0.699 0.334 1.4 1.11 1.04 0.921 1.03 0.991 1.38 1.57 0.046 0.02 0.161 0.154 0.228 0.189 0.302 0.415 0.418 0.42 0.367 - 2.83 K

Payout Ratio

8.63 2.62 0.0 1.88 0.005 1.33 - 5.13 0.17 -3.56 0.819 -0.001 - -0.0 - -0.068 -0.133 0.425 0.425 0.538 -0.067 0.422 0.422 0.063 0.063 0.065 0.065 0.029 0.044

Dividend Yield

0.031 0.0 0.0 0.074 0.0 0.059 - 0.089 0.021 0.088 0.036 0.0 - 0.0 - 0.014 0.014 0.039 0.031 0.015 0.015 0.018 0.013 0.002 0.002 0.004 0.004 11.3 22.7

Current Ratio

5 7.56 5.58 9.22 5.84 8.75 6.53 5.75 5.24 5.02 4.52 4.95 4.2 5.72 2.55 3.11 1.88 1.82 1.88 2.44 3.06 2.94 2.92 2.9 2.21 1.73 2.01 - 2.35

Quick Ratio

3.23 4.65 3.41 5.61 3.51 4.92 3.69 3.14 2.63 2.67 2.1 2.12 2.02 2.26 1.31 1.26 0.714 0.796 1.08 1.45 1.83 1.97 1.87 1.74 1.21 0.838 0.972 - 1.29

Cash Ratio

0.643 0.874 0.839 0.872 0.643 0.474 0.231 0.025 0.305 0.166 0.088 0.041 0.055 0.061 0.087 0.385 0.007 0.002 0.019 0.021 0.037 0.031 0.052 0.077 0.063 0.054 0.057 - 0.06

Days Of Sales Outstanding, DSO

- 126 K 89 108 105 117 139 121 74.6 85.7 62.6 62.8 71.8 58.3 101 46.2 65 - - - - 90.2 92.6 95.1 80.3 65.1 62.2 - 55.3

Days Of Inventory Outstanding, DIO

240 274 K 255 239 311 318 476 324 222 226 291 245 230 241 231 272 487 232 187 259 743 138 141 136 145 159 151 - 122

Days Of Payables Outstanding, DPO

37.9 10.7 K 12.3 20.4 10.9 59.9 74.2 90.6 13.5 44.1 15.2 52 30 20.5 115 41.3 84.9 34.9 26 23.5 97.9 24.3 16.7 8.65 9.68 11.1 11.5 - 9.25

Operating Cycle

240 401 K 344 347 416 436 615 445 296 312 354 308 302 300 331 319 552 232 187 259 743 228 234 231 225 224 213 - 177

Cash Conversion Cycle

202 390 K 332 326 405 376 540 354 283 267 339 256 272 279 217 277 467 197 161 235 645 204 217 223 215 213 202 - 168

Gross Profit Margin

0.536 0.547 0.566 0.53 0.632 0.618 0.642 0.642 0.437 0.555 0.596 0.478 0.52 0.448 0.455 0.584 0.668 0.546 0.546 0.635 0.665 0.541 0.541 0.514 0.514 0.534 0.534 0.583 0.611

Operating Profit Margin

0.003 0.108 0.061 0.056 0.242 0.131 0.04 0.073 0.083 0.015 0.13 -0.19 0.053 -0.026 0.127 0.165 0.003 0.143 0.143 0.145 0.182 0.188 0.188 0.195 0.195 0.336 0.336 0.205 0.264

Pretax Profit Margin

0.024 0.126 0.09 0.119 0.258 0.141 0.069 0.089 0.155 0.045 0.075 -0.176 0.084 -0.039 -0.25 -0.059 -0.177 0.063 0.063 0.034 -0.317 0.097 0.097 0.107 0.107 0.263 0.263 0.206 0.236

Net Profit Margin

0.015 0.103 0.052 0.097 0.202 0.098 0.037 0.023 0.169 -0.024 0.052 -0.163 0.075 -0.083 -0.225 -0.144 -0.098 0.045 0.045 0.016 -0.335 0.082 0.082 0.105 0.105 0.24 0.24 0.141 0.175

Effective Tax Rate

0.372 0.227 0.375 0.252 0.217 0.369 0.449 0.719 -0.097 1.42 0.401 0.219 0.096 -1.19 0.207 -1.43 0.903 0.281 0.281 0.489 -0.062 0.252 0.252 0.215 0.215 0.112 0.112 0.301 0.259

Return On Assets, ROA

0.003 0.0 0.011 0.02 0.043 0.021 0.006 0.005 0.039 -0.007 0.012 -0.037 0.019 -0.02 -0.051 -0.039 -0.017 0.011 0.011 0.004 -0.03 0.018 0.018 0.024 0.025 0.06 0.069 - 0.077

Return On Equity, ROE

0.004 0.0 0.013 0.023 0.051 0.024 0.007 0.006 0.048 -0.008 0.015 -0.045 0.024 -0.024 -0.073 -0.051 -0.025 0.017 0.017 0.006 -0.051 0.035 0.035 0.045 0.046 0.109 0.121 - 0.123

Return On Capital Employed, ROCE

0.001 0.0 0.015 0.012 0.058 0.03 0.007 0.018 0.022 0.005 0.035 -0.049 0.016 -0.007 0.039 0.054 0.001 0.051 0.049 0.045 0.02 0.048 0.049 0.053 0.058 0.11 0.122 - 0.149

Net Income Per Ebt

0.628 0.815 0.574 0.817 0.781 0.695 0.532 0.264 1.09 -0.538 0.693 0.929 0.896 2.13 0.901 2.44 0.555 0.705 0.705 0.484 1.06 0.851 0.851 0.985 0.985 0.912 0.912 0.684 0.741

Ebt Per Ebit

7.37 1.17 1.47 2.13 1.07 1.07 1.71 1.23 1.88 2.94 0.581 0.923 1.6 1.5 -1.97 -0.359 -56.3 0.442 0.442 0.232 -1.75 0.516 0.516 0.545 0.545 0.783 0.783 1.01 0.894

Ebit Per Revenue

0.003 0.108 0.061 0.056 0.242 0.131 0.04 0.073 0.083 0.015 0.13 -0.19 0.053 -0.026 0.127 0.165 0.003 0.143 0.143 0.145 0.182 0.188 0.188 0.195 0.195 0.336 0.336 0.205 0.264

Debt Ratio

- - 0.0 0.033 - 0.001 0.029 0.006 0.026 0.05 0.041 0.034 0.023 0.01 0.008 0.011 0.17 0.179 0.238 0.299 0.323 0.205 0.195 0.183 0.177 0.171 0.192 - 0.178

Debt Equity Ratio

- - 0.0 0.038 - 0.001 0.035 0.007 0.032 0.061 0.05 0.041 0.028 0.012 0.012 0.015 0.248 0.27 0.382 0.507 0.551 0.402 0.37 0.337 0.324 0.31 0.34 - 0.284

Long Term Debt To Capitalization

- - - 0.033 - - 0.027 0.027 0.006 0.006 0.006 0.005 0.005 0.005 0.005 0.005 0.005 0.004 0.06 0.173 0.231 0.199 0.186 0.173 0.115 0.042 0.111 - 0.112

Total Debt To Capitalization

- - 0.0 0.037 - 0.001 0.034 0.007 0.031 0.057 0.048 0.039 0.028 0.012 0.012 0.014 0.199 0.213 0.276 0.336 0.355 0.287 0.27 0.252 0.245 0.237 0.254 - 0.221

Interest Coverage

- - - 28.8 176 - - 0.055 0.012 - - -3 - - - - - 1.95 1.95 - - 3.25 3.25 3.23 3.23 4.52 4.52 165 10.4

Cash Flow To Debt Ratio

- - 1.58 K 0.787 - 47.2 0.723 5.59 3.3 0.725 - 0.002 -0.001 -0.002 -0.002 - - - - - - - - - - - - - -

Company Equity Multiplier

1.25 1.17 1.22 1.15 1.21 1.16 1.18 1.2 1.21 1.21 1.23 1.21 1.24 1.19 1.43 1.31 1.46 1.5 1.6 1.7 1.71 1.96 1.9 1.84 1.83 1.81 1.77 - 1.6

Receivables Turnover

- 0.001 1.01 0.834 0.855 0.767 0.648 0.745 1.21 1.05 1.44 1.43 1.25 1.54 0.895 1.95 1.38 - - - - 0.997 0.972 0.946 1.12 1.38 1.45 - 1.63

Payables Turnover

2.37 0.008 7.33 4.42 8.25 1.5 1.21 0.994 6.66 2.04 5.9 1.73 3 4.39 0.784 2.18 1.06 2.58 3.46 3.82 0.919 3.71 5.39 10.4 9.3 8.11 7.81 - 9.73

Inventory Turn Over

0.376 0.0 0.353 0.377 0.29 0.283 0.189 0.278 0.406 0.398 0.309 0.367 0.392 0.373 0.39 0.33 0.185 0.388 0.481 0.348 0.121 0.652 0.638 0.66 0.622 0.568 0.596 - 0.737

Fixed Asset Turnover

1.07 0.001 1.15 1.09 1.15 1.11 0.802 1.17 1.3 1.55 1.5 1.4 1.71 1.53 1.71 1.95 1.45 2.19 2.15 2.1 0.804 1.59 1.65 1.71 1.73 1.76 1.85 - 2.2

Asset Turnover

0.191 0.0 0.21 0.207 0.212 0.214 0.151 0.222 0.233 0.27 0.238 0.227 0.259 0.245 0.228 0.269 0.174 0.254 0.245 0.232 0.089 0.214 0.222 0.231 0.24 0.251 0.286 - 0.441

Operating Cash Flow Sales Ratio

0.006 0.149 0.218 0.126 0.226 0.197 0.14 0.14 0.373 0.135 - 0.0 -0.0 -0.0 -0.0 - - - - - - - - - - - - - -

Free Cash Flow Operating Cash Flow Ratio

-10.4 0.95 0.987 0.851 0.924 0.982 1 1.1 0.948 0.942 - 0.757 1.27 1 1.05 - - - - - - - - - - - - - -

Cash Flow Coverage Ratios

- - 1.58 K 0.787 - 47.2 0.723 5.59 3.3 0.725 - 0.002 -0.001 -0.002 -0.002 - - - - - - - - - - - - - -

Short Term Coverage Ratios

- - - 8.68 - 47.2 3.68 5.59 4.12 0.809 - 0.002 -0.001 -0.004 -0.004 - - - - - - - - - - - - - -

Capital Expenditure Coverage Ratio

0.088 0.02 77.5 6.69 13.2 56.5 - 9.97 19.1 17.1 - 4.11 -3.71 - -20.6 - - - - - - - - - - - - - -

Dividend Paid And Capex Coverage Ratio

0.029 0.019 77 0.625 12.4 1.47 - 1.04 7.73 1.43 - 1.66 -3.71 -2.06 K -20.6 - - - - - - - - - - - - - -

Dividend Payout Ratio

8.63 2.62 0.0 1.88 0.005 1.33 - 5.13 0.17 -3.56 0.819 -0.001 - -0.0 - -0.068 -0.133 0.425 0.425 0.538 -0.067 0.422 0.422 0.063 0.063 0.065 0.065 0.029 0.044

Price To Free Cash Flows Ratio, P/FCF

-72.8 19.1 K 11.5 23.1 14.4 11.3 16.7 8.75 3.81 7.79 -58.8 6.12 K -13.2 K -7.24 K -8.18 K 7.42 7.45 11.8 14.8 -21.7 -22.7 -466 -635 -343 -322 -265 -265 -0.034 -0.017

Price To Operating Cash Flows Ratio, P/OCF

757 18.2 K 11.3 19.7 13.3 11.1 16.7 9.62 3.61 7.34 - 4.63 K -16.8 K -7.24 K -8.58 K - - - - - - - - - - - - - -

Price Cash Flow Ratio, P/CF

757 18.2 K 11.3 19.7 13.3 11.1 16.7 9.62 3.61 7.34 - 4.63 K -16.8 K -7.24 K -8.58 K - - - - - - - - - - - - - -

Enterprise Value Multiple, EV

92.9 17.2 K 20.9 29.5 9.19 9.17 27.9 17.3 9.91 23.1 7.05 -21.1 6.46 22.8 5.4 -3.67 96.3 8.22 10.8 10.8 23.6 17.8 21.6 27.7 25.9 12 12 - 1.43

Price Fair Value, P/FV

1.01 0.582 0.632 0.588 0.767 0.541 0.419 0.357 0.379 0.322 0.346 0.345 0.256 0.211 0.239 0.247 0.236 0.184 0.236 0.222 0.229 0.816 1.12 1.65 1.6 1.71 1.9 - 0.0

All numbers in RUB currency

Multiples are an important financial analysis tool for the company Завод ДИОД, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.01 3.72 % $ 233 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.2 4.41 % $ 7.7 B australiaAustralia
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.94 -1.52 % $ 495 M britainBritain
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.08 -3.15 % $ 5.89 M chinaChina
BioVie BioVie
BIVI
$ 1.14 1.04 % $ 1.68 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.5 1.52 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.2 6.7 % $ 435 M israelIsrael
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.56 -0.34 % $ 761 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.04 -0.26 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.82 -0.67 % $ 1.3 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Certara Certara
CERT
$ 8.82 -0.4 % $ 1.41 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.57 0.21 % $ 140 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.8 0.34 % $ 116 M franceFrance
Axon Enterprise Axon Enterprise
AXON
$ 572.17 0.01 % $ 43.3 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.57 0.78 % $ 16.1 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.14 -0.4 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.91 -1.11 % $ 1.46 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.28 3.22 % $ 1.76 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.63 -0.09 % $ 752 M usaUSA